DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0226916A1 Cochrum Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0226916A1 Cochrum Et Al US 2005O226916A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0226916A1 Cochrum et al. (43) Pub. Date: Oct. 13, 2005 application No. 09/290,846, filed on Apr. 13, 1999, (4) HEMOSTATIC POLYMER USEFUL FOR now abandoned. RAPID BLOOD COAGULATION AND HEMOSTASIS (60) Provisional application No. 60/108,185, filed on Nov. 12, 1998. (76) Inventors: Kent C. Cochrum, Davis, CA (US); Robert A. Gunther, Davis, CA (US); Publication Classification Susan A. Jemtrud, San Francisco, CA (US); Franklin M. Beninsig, Sacramento, CA (US) (51) Int. Cl. ............................................... A61K 9/00 Correspondence Address: (52) U.S. Cl. .............................................................. 424/445 FISH & RICHARDSON P.C. PO BOX 1022 MINNEAPOLIS, MN 55440-1022 (US) (57) ABSTRACT Appl. No.: 11/145,678 (21) Provided herein is a novel hemostatic polymer composition (22) Filed: Jun. 6, 2005 comprising a Substance containing uncharged organic hydroxyl groups and a Substance containing at least one of Related U.S. Application Data a halogen atom and an epoxy group, which is characterized as inducing rapid blood coagulation and hemostasis at a (63) Continuation of application No. 09/438,872, filed on wound or bleeding site. Methods of use of the novel polymer Nov. 12, 1999, which is a continuation-in-part of composition are also provided. Patent Application Publication Oct. 13, 2005 Sheet 1 of 11 US 2005/0226916A1 INJURY TOBLOOD VESSELWALL confictionWASO COLLAGEN SURFACE N-a1YANANN CONTACT REACTION PLATELET ADHESION INTRINSIC EXTRINSIC DEGRANULATION PATH WAY PATHWAY SERONTONIN N7 EXPOSED PLATELET PHOSPHOLLPD COMMON PLATELET ADHERENCE w PATH WAY FIRMAGG AGGREGATION AGGLUTINATION STABLE FIBRN PLATELET X111A Most PLUG CLOT THE END REACTIONS REACTIONS REQUIRING CALCIUM W = von WILLEBRAND FACTOR T = ACTIVATED THROMBIN HEMOSTATICREACTIONS. FIG. 1A Patent Application Publication Oct. 13, 2005 Sheet 2 of 11 US 2005/022691.6 A1 TISSUE ANDBLOOD VESSELINJURY EXTRINSIC INTRINSIC VASOCONSTRICTION POLYMER COLLAGEN EXPOSURE 5 HYDROXY ESEP m TRYPTAMINE HROMBOPLASTIN (FACTOR III) XI ACTIVE PLATELET/POLYMER A. (t) ADHESION CHARGE AGGREGATE 2 ACTIVATESTISSUEAisii) /X PLATEET RELEASE V IX PF3PLATELET PROTHROMBIN 2)2. ACCELERATES V / ACTIVATOR ADP THROMBIN yWF (EARLYRY THROMBIN)N / m FURTHERAGGREGATION X yPF 3PLATELETSURFACE E:MARY HEMESAT THROMBOPASIN PLAELET/POLYMER PROTHROMBIN---THROMBIN (MOST THROMBIN real PLATELETSURFACE FBRINOGEN - AX --> FIBRIN-> IRREVERSIBLE (CONCENTRATED AROUND PAELETPOLYMER POLYMER SPHERES) FBRIN CLOT t PLASMINOGEN -> PLASMIN /THROMBASTHENN CLOT RETRACTION PLASMINOGEN FBRINOGEN ACTIVATOR DEGRADATIONFBRIN * PRODUCTS FIG. 1B Patent Application Publication Oct. 13, 2005 Sheet 3 of 11 US 2005/022691.6 A1 v?}?NalogºOrde SHEGHNEÐVT100'SSVIÐ-SHOWHºlms-TGVLIEMGEÐJWHO“. BoyºwnswrBHIOONa ATHAILy?ENOHIO-Txa01000139NISOdXBAGOJIIANIW?DK-1/x ENYHENENÝSwidlal?y?àº, dMWNEÐÝTTOO IIX|0d --~~~~~~)NOLLYWHOHSN\/81-¿ONO|1\!/\|1OW<---- NOl?y?m.GOWHONOLIIGIHNI<-------- Patent Application Publication Oct. 13, 2005 Sheet 5 of 11 US 2005/0226916A1 ------ HEMOSTATIC HEMOSTATICZONE ZONE TOP VIEW HEMEXBAG (REAGENT ZONE) SDE VIEW FIG. 4A FIG. 4B 18-13 18-14 E. ENLARGED WEWS OF COVERING SEPARATION MATERAL (EXAMPLES OF DIFFERENT MATRIXTEXTURES) FIG. 5A FIG. 5B FIG. 5C Patent Application Publication Oct. 13, 2005 Sheet 6 of 11 US 2005/022691.6 A1 SUBSTRATE 16 6(a) HEMOSTATICZONE 12 FIG. 6A SUBSTRATE 17 HEMOSTATIC ZONE 12 E: D O-O-(/) O-K X-O-O-O-O E788 RSRSRSRSRSR38888-CGC&88888.O-O-O-O-O O-O-O-O-KX-OSRRSRRS RS RSRSRSRSRSR 88.8888. RSRSRSRSRSR 88.8888 ES-88SRSRSRSRSRSRSRSRSRSRSR B8888.88888.8888.888RRRRRRRRRRRRRRR HEMEXBAG (REAGENT ZONE) ON ADHESIVE BACKING FIG. 6B Patent Application Publication Oct. 13, 2005 Sheet 7 of 11 US 2005/022691.6 A1 18 SEPARATION MATRIX SIZE OF PORE OR XXXXXXXXXXX: WEAVE OPENING 22 xxxx & SSXxxxxxxxxx& & SIZE OF WEAVE S&SX& &&xxxxxxx SSXXXXXXXXXS.& S&S& g xxx xxxx MATRIXMATERAL 23 &XXXXXX XX g xxxx xxx S&SxSXX.& xxxx TOP VIEW vol. OF MATRX 18 FIG. 7A SDEVIEW m FIG. 7B Patent Application Publication Oct. 13, 2005 Sheet 8 of 11 US 2005/0226916A1 MODIFIED SYRINGE CURVEDTP PLUNGER21 FOR USE ON ARTERIESNEINS (SIDE VIEW) SYRINGE19 HEMOSTATIC ACCELERANT20 SEPARATION MATRIX (TOP VIEW) FIG. 8B SEPARATION MATRIX (E.G. SILK) 18 FIG. 8A Patent Application Publication Oct. 13, 2005 Sheet 9 of 11 US 2005/022691.6 A1 - II Y I A Patent Application Publication Oct. 13, 2005 Sheet 10 of 11 US 2005/022691.6 A1 Patent Application Publication Oct. 13, 2005 Sheet 11 of 11 US 2005/022691.6 A1 PLATELET ACTIVATION BY THE LONIC CONCENTRATION OF FIBRINOGEN ON THE SURFACE OF FILBRINOGEN (NEGATIVE CHARGE), MW 340,000 PLATELET (ACTIVATED BY NEGATIVELY CHARGED SURFACE) SEPHADEX G-150: ABSORBS PROTEINS < 300,000 MW AND CONCENTRATES PROTEINS D 300,000MW FIG 11 US 2005/022691.6 A1 Oct. 13, 2005 HEMOSTATIC POLYMER USEFUL FOR RAPID below, conventional methods for controlling bleeding are BLOOD COAGULATION AND HEMOSTASS fraught with numerous drawbackS. 0001. This application claims priority of provisional 0012. A conventional method of controlling topical application No. 60/108,185, filed Nov. 12, 1998 and pending bleeding including external hemorrhage advocates the use of application Ser. No. 09/290,846, Filed Apr. 13, 1999, each of cotton gauze pads capable of absorbing 250 ml of blood. which is incorporated by reference herein. Such use is very common in the armed forces and particu larly in civilian trauma units. However, cotton pads are BACKGROUND OF THE INVENTION generally considered passive dressings, because of their 0002 The present invention relates to a novel hemostatic inability to initiate or accelerate blood clotting. polymer composition comprising of a Substance containing 0013 Another method of controlling bleeding (i.e., uncharged organic hydroxyl groups and a Substance con wound closure) advocates the use of Surgical Sutures and taining at least one of a halogen atom and/or an epoxy group. Staples. Sutures are recognized to provide adequate wound The polymer is especially useful for the rapid induction of Support; however, Sutures cause additional trauma to the blood coagulation and hemostasis at a wound or bleeding wound Site (by reason of the need for the needle and Suture Site. Methods of using the hemostatic polymer are also to pass through tissue) and are time-consuming to place, provided. and, at Skin level, can cause unattractive wound closure markS. Surgical Staples have been developed to Speed wound 0003) 1. Field of the Invention apposition and provide improved cosmetic results, these are 0004 Wound healing refers to a complex series of bio known to impose additional wound trauma and require the chemical and cellular events, which result in the contracting, use of ancillary and often expensive devices for positioning closing and healing of a wound, which, in itself, is a and applying them. traumatic insult to the integrity of a tissue. Wound manage ment, contemplates protecting the wound from additional 0014 Wound healing is a complex process involving Such factors as cells, extracellular matrix (ECM) compo trauma and/or environmental factors that may delay the nents and the cellular microenvironment. ESSentially, all healing process. Towards this end, it advocates a combined wound healing involves the repair or replacement of dam Systemic and local approach to facilitate wound healing, aged tissues. The precise nature of Such repair or replace which includes the use of antibiotics and the application of ment depends upon the tissues involved, although all Such a Suitable dressing. processes involve certain basic principles. 0005 The principal function of a wound dressing is to provide an optimum healing environment by mimicking a 0015. By way of background, as a part of bemostasis, clot natural barrier function of the epithelium. Accordingly, in formation is often a life-Saving process in response to practice, a wound dressing should, at a minimum: trauma and serves to arrest the flow of blood from severed vasculature. In addition, it is often desirable to initiate or 0006 i) control bleeding, enhance the body's natural hemostatic process. For example, 0007 ii) isolate and protect the wound or bleeding after Severe trauma, a victim may require Supplemental Site from the external environment before healing assistance in Stopping bleeding or hemorrhage caused by the can begin trauma. 0016 Blood coagulation occurs by means of a complex 0008 iii) prevent further contamination or infection cascade of reactions called the coagulation cascade which and involves the formation of the enzyme thrombin, which is 0009 iv) maintain a moist micro-environment next formed from prothrombin via the interactions of factor Xa, to the wound Surface. calcium and other ancillary Substances. For an excellent review of the blood coagulation cascade, the reader is 0010. It is well accepted that wound healing may be directed to the article by Mann, K. G., XVII Congress of the impeded by an infection, at the wound or bleeding site, International Society on Thrombosis and Haemostasis, Med because it facilitates further tissue damage and promotes scape, 1999, the entire contents of which are incorporated by inflammation. Such contamination may result from contact reference herein. with an infected object or the ingreSS of dirt, dust, or microorganism, either at the time of injury or later from the 0017. In wound healing, the final stage of the coagulation Subjects own skin. AS consequence, Subsequent further cascade results in the formation
Load more

Recommended publications
  • Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma: a Single-Centre, Observer-Blinded, Randomized Controlled Trial (Trace)
    TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) by Adriana Micheline Workewych A thesis submitted in conformity with the requirements for the degree of Master of Science Institute of Medical Science University of Toronto © Copyright by Adriana Micheline Workewych 2018 TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) Adriana Micheline Workewych Master of Science Institute of Medical Science University of Toronto 2018 ABSTRACT Chronic subdural hematoma (CSDH) is a frequent consequence of head trauma, particularly in older individuals. Given the aging of populations globally, its incidence is projected to increase substantially. Hyperfibrinolysis may be central to CSDH enlargement by causing excessive clot degradation and liquefaction, impeding resorption. The only current standard treatment for CSDH is surgery, however, up to 31% of residual hematomas enlarge, requiring reoperation. Tranexamic acid (TXA), an antifibrinolytic medication that prevents excessively rapid clot breakdown, may help prevent CSDH enlargement, potentially eliminating the need for repeat surgery. To evaluate the feasibility of conducting a trial investigating TXA efficacy in residual CSDH, we conducted an observer-blinded, pilot randomized controlled trial (RCT). We showed this trial was feasible and safe, reporting only minor to moderate AEs, and an attrition rate of 4%. The results from this study will inform the conduct of a double-blinded RCT investigating TXA efficacy in post-operative CSDH management. ii ACKNOWLEDGEMENTS First, I would like to thank my supervisor Dr. Michael Cusimano, my mentor for nearly six years. You have always given me more opportunity than I could have ever hoped for – I could not ask for a more dedicated teacher.
    [Show full text]
  • Path Ggf 5 2020.Pdf
    Hemostasis Hemostasis and Thrombosis Normal hemostasis is a consequence of tightly regulated processes that maintain blood in a fluid state in normal vessels, yet also permit the rapid formation of a hemostatic clot at the site of a vascular injury. Thrombosis involves blood clot formation within intact vessels. Both hemostasis and thrombosis involve three components: the vascular wall, platelets and the coagulation cascade. Elements of the Hemostatic process • Endothelium • Anti-thrombosis • Pro-thrombosis • Platelets • Platelet-endothelial cell interaction • Coagulation cascade http://www.as.miami.edu/chemistry/2086/chapter_21/NEW-Chap21_class_part1_files/image002.jpg After initial injury there is a brief period of arteriolar vasoconstriction mediated by reflex neurogenic mechanisms and augmented by the local secretion of factors such as endothelin (a potent endothelium-derived vasoconstrictor) The effect is transient, however, and bleeding would resume if not for activation of the platelet and coagulation systems. Endothelial injury exposes highly thrombogenic subendothelial extracellular matrix (ECM), facilitating platelet adherence and activation. Activation of platelets results in a dramatic shape change (from small rounded discs to flat plates with markedly increased surface area), as well as the release of secretory granules. Within minutes the secreted products recruit additional platelets (aggregation) to form a hemostatic plug; this process is referred to as primary hemostasis. http://www.ouhsc.edu/platelets/Platelet%20Pic s/Platelets3.jpg http://medcell.med.yale.edu/histology/blood_bone_marr ow_lab/images/platelets_em.jpg Tissue factor is also exposed at the site of injury. Also known as factor III and thromboplastin, tissue factor is a membrane-bound procoagulant glycoprotein synthesized by endothelial cells. It acts in conjunction with factor VII (see below) as the major in vivo initiator of the coagulation cascade, eventually culminating in thrombin generation.
    [Show full text]
  • The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation Using ADP
    RESEARCH ○○○○○○○○ The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation using ADP ROBERT F CORNELL, TIM R RANDOLPH ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ OBJECTIVE: Determine the minimum concentration of plasma INDEX TERMS: ADP; aggregation; fibrinogen; platelets. fibrinogen needed to stimulate the aggregation of platelets, col- lected from normal subjects, using ADP. Clin Lab Sci 2001;15(1):30 DESIGN: Platelet rich plasmas (300 x 109 platelets/L) were made Robert F Cornell II was a student in the Department of Clinical and adjusted to final fibrinogen concentrations of 75, 19, 5, and 0 Laboratory Science, Saint Louis University Health Sciences Center, St mg/dL using fibrinogen free serum. Each fibrinogen concentra- Louis MO when this research was done. Downloaded from tion in all twelve subjects was aggregated with ADP. Tim R Randolph MS is an Assistant Professor in the Department of SETTING: Research laboratory in the Department of Clinical Clinical Laboratory Science, School of Allied Health Professions, Saint Laboratory Science at Saint Louis University. Louis University Health Sciences Center, St Louis MO. PARTICIPANTS: Twelve healthy volunteers of both genders, be- Address for correspondence: Tim R Randolph MS, Saint Louis Uni- http://hwmaint.clsjournal.ascls.org/ tween the ages of 18 and 60 years who were not pregnant and versity School of Allied Health Professions, Department of Clinical Labo- weighed at least 110 pounds were included in the study. Subjects ratory Science, Room 3096, 3437 Caroline St, St Louis MO 63104. were excluded from the study if they had ingested aspirin within (314) 577-8518, (314) 577-8503 (fax). [email protected] one week prior to blood collection.
    [Show full text]
  • Biomechanical Thrombosis: the Dark Side of Force and Dawn of Mechano-­ Medicine
    Open access Review Stroke Vasc Neurol: first published as 10.1136/svn-2019-000302 on 15 December 2019. Downloaded from Biomechanical thrombosis: the dark side of force and dawn of mechano- medicine Yunfeng Chen ,1 Lining Arnold Ju 2 To cite: Chen Y, Ju LA. ABSTRACT P2Y12 receptor antagonists (clopidogrel, pras- Biomechanical thrombosis: the Arterial thrombosis is in part contributed by excessive ugrel, ticagrelor), inhibitors of thromboxane dark side of force and dawn platelet aggregation, which can lead to blood clotting and A2 (TxA2) generation (aspirin, triflusal) or of mechano- medicine. Stroke subsequent heart attack and stroke. Platelets are sensitive & Vascular Neurology 2019;0. protease- activated receptor 1 (PAR1) antag- to the haemodynamic environment. Rapid haemodynamcis 1 doi:10.1136/svn-2019-000302 onists (vorapaxar). Increasing the dose of and disturbed blood flow, which occur in vessels with these agents, especially aspirin and clopi- growing thrombi and atherosclerotic plaques or is caused YC and LAJ contributed equally. dogrel, has been employed to dampen the by medical device implantation and intervention, promotes Received 12 November 2019 platelet thrombotic functions. However, this platelet aggregation and thrombus formation. In such 4 Accepted 14 November 2019 situations, conventional antiplatelet drugs often have also increases the risk of excessive bleeding. suboptimal efficacy and a serious side effect of excessive It has long been recognized that arterial bleeding. Investigating the mechanisms of platelet thrombosis
    [Show full text]
  • BLOOD COAGULATION TESTS 17 Lea E
    HEMATOLOGY: BLOOD COAGULATION TESTS 17 Lea E. Dela Peña Normal hemostasis involves a complex interaction among the vascular subendothe- OBJECTIVES lium, platelets, coagulation factors, and proteins that promote clot formation, clot degradation and inhibitors of these substances. Disruption in normal hemostasis can After completing this chapter, the result in bleeding or excessive clotting. Bleeding can be caused by trauma or damage reader should be able to to vessels, acquired or inherited deficiencies of coagulation factors, or physiological • Describe the role of platelets, disorders of platelets, whereas excessive clotting can result from abnormalities of the the coagulation cascade, and vascular endothelium, alterations in blood flow, or deficiencies in clotting inhibitors. fibrinolytic system in normal Clinicians must monitor the hemostasis process in individual patients to ensure hemostasis their safety from an imbalance in this complex system. For example, practitioners routinely order platelet tests in patients on certain antineoplastic medications to • List the laboratory tests used assess for thrombocytopenia. Likewise, clinicians closely monitor coagulation tests to assess platelets and discuss for patients receiving anticoagulants to prevent thromboembolic or hemorrhagic factors that may influence their complications. Overall, the hemostatic process is intricate and requires a clinician results knowledgeable in its dynamics for quality assessment. • List the laboratory tests used This chapter reviews normal coagulation physiology,
    [Show full text]
  • The Molecular Basis of Blood Coagulation Review
    Cell, Vol. 53, 505-518, May 20, 1988, Copyright 0 1988 by Cell Press The Molecular Basis Review of Blood Coagulation Bruce Furie and Barbara C. Furie into the fibrin polymer. The clot, formed after tissue injury, Center for Hemostasis and Thrombosis Research is composed of activated platelets and fibrin. The clot Division of Hematology/Oncology mechanically impedes the flow of blood from the injured Departments of Medicine and Biochemistry vessel and minimizes blood loss from the wound. Once a New England Medical Center stable clot has formed, wound healing ensues. The clot is and Tufts University School of Medicine gradually dissolved by enzymes of the fibrinolytic system. Boston, Massachusetts 02111 Blood coagulation may be initiated through either the in- trinsic pathway, where all of the protein components are present in blood, or the extrinsic pathway, where the cell- Overview membrane protein tissue factor plays a critical role. Initia- tion of the intrinsic pathway of blood coagulation involves Blood coagulation is a host defense system that assists in the activation of factor XII to factor Xlla (see Figure lA), maintaining the integrity of the closed, high-pressure a reaction that is promoted by certain surfaces such as mammalian circulatory system after blood vessel injury. glass or collagen. Although kallikrein is capable of factor After initiation of clotting, the sequential activation of cer- XII activation, the particular protease involved in factor XII tain plasma proenzymes to their enzyme forms proceeds activation physiologically is unknown. The collagen that through either the intrinsic or extrinsic pathway of blood becomes exposed in the subendothelium after vessel coagulation (Figure 1A) (Davie and Fiatnoff, 1964; Mac- damage may provide the negatively charged surface re- Farlane, 1964).
    [Show full text]
  • Topic: Bleeding 2015
    Department of General Surgery Medical Academy named after S.I. Georgievskiy, The Federal State Autonomous Educational Establishment of Higher Education “Crimean Federal University named after V.I. Vernadsky” Ministry of Education and Science of the Russian Federation For the 3rd year students The text of the lectures and the minimum amount of knowledge necessary for a understanding of the subject material. Topic: Bleeding Authors: prof.Mikhailychenko V.Yu, Starykh A.A. 2015 Bleeding Bleeding, technically known as hemorrhaging or hæmorrhaging (see American and British spelling differences), is blood escaping from the circulatory system. Etiology : trauma and some diseases (tuberculosis, cancer, peptic ulcer). What is blood? Functions of blood. Blood is basically a type of a connective tissue which is found in the human body in fluid state. It is made up of plasma which is a highly viscous liquid and 3 different types of blood cells that are floating around in it. Almost 92% of the plasma is water while the rest consists of enzymes, hormones, antibodies, nutrients, gases, salts, proteins and metabolites of various kinds. Besides plasma, the cellular constituents of blood are red and white blood cells and platelets. What are the functions of blood? What about the functions for each blood component? Functions of Blood Blood performs many important functions within the body including: Supply of oxygen to tissues (bound to hemoglobin, which is carried in red cells) Supply of nutrients such as glucose, amino acids, and fatty acids (dissolved in the blood or bound to plasma proteins (e.g., blood lipids)) Removal of waste such as carbon dioxide, urea, and lactic acid Immunological functions, including circulation of white blood cells, and detection of foreign material by antibodies Coagulation, the response to a broken blood vessel, the conversion of blood from a liquid to a semi-solid gel to stop bleeding.
    [Show full text]
  • Hemostasis at a Glance ❯❯ Cody Alcott, DVM ❯❯ Charles Brockus, DVM, ❯❯ Brett Sponseller, DVM, Response to Initial David M
    3 CE CREDITS CE Article 2 Hemostasis At a Glance ❯❯ Cody Alcott, DVM ❯❯ Charles Brockus, DVM, ❯❯ Brett Sponseller, DVM, Response to initial David M. Wong, DVM, PhD, DACVIM, DACVP PhD, DACVIM MS, DACVIM Charles River Labs Iowa State University vascular injury Sparks, Nevada Page 78 Iowa State University Platelet plug formation Abstract: Hemostasis, the coagulation cascade, and clot formation present a daunting list of and primary hemostasis Page 79 factors, pathways, and interactions to equine clinicians. A basic knowledge of hemostasis is necessary to evaluate various disease processes in horses. Initial injury to the vascular en- Endothelial cell reactions Page 80 dothelium results in local vasoconstriction and formation of a platelet plug. This initial response reduces blood loss from the damaged vessel but may be inadequate at maintaining hemostasis Secondary hemostasis alone. Therefore, the intrinsic, extrinsic, and common coagulation pathways interact with one Page 80 another to form thrombin and ultimately stabilize the platelet plug. Thrombin accomplishes this The coagulation cascade: by converting soluble fibrinogen to insoluble fibrin, resulting in clot stabilization. Alternatively, the extrinsic pathway fibrinolysis promotes resolution of clot formation. Because of multiple positive and negative Page 80 feedback interactions as well as multiple circulating mediators and inhibitors, coagulation and The coagulation cascade: fibrinolysis are finely controlled systems in healthy patients. However, perturbations of the the intrinsic pathway coagulation cascade in disease states can result in severe complications or death. Page 81 Common pathway lterations in coagulation and Response to Initial Vascular Injury Page 81 fibrinolysis are relatively uncom- The main function of the coagulation sys- Clot formation Amon in horses, but when they tem is to control hemorrhage from the Page 82 occur, especially in critically ill patients, vascular endothelium when it has been T h r o m b i n general knowledge of the associated damaged by trauma or inflammation.
    [Show full text]
  • 3.6.4 Hemostasis
    3.6.4 Hemostasis Hemostasis, or the cessation of bleeding, is critical to the survival of the human organism. If the mechanisms of hemostasis were completely taken away, a mere paper cut could ultimately lead an individual to bleed to death. Luckily, the mechanisms of hemostasis function properly for most individuals. Hemostasis can be divided into three steps: vascular spasm, development of a platelet plug, and blood clot formation. Vascular Spasm Upon incurring some type of trauma, blood flow through damaged vessels is immediately limited through a process known as vascular spasm. During a vascular spasm, pain can cause reflexes in the nervous system to stimulate smooth muscle contraction around the blood vessel. As the smooth muscle of the impaired vessels contract, the diameter of the vessels decrease. In some instances, the blood vessel can be entirely occluded by a vascular spasm. However, this occlusion is short lived and the smooth muscle will eventually relax and then bleeding out of the damaged vessel can greatly increase. As effective as a vascular spasm is, it is temporary and cannot establish hemostasis alone. Platelet Plug BIO 461 Principles of Physiology 1 Formation of Platelet Plug Image drawn by BYU-Idaho student Nate Shoemaker Spring 2016 The image above shows a blood vessel in longitudinal section. Number one shows how platelets begin to converge, slow down and roll along the vessel wall near the damaged area. Platelets begin to attach to the collagen in the damaged area and this activates them. Activated platelets experience a physical shape change and are able to attract other platelets to attach to them and to any other exposed collagen.
    [Show full text]
  • Coagulation Simplified…
    Coagulation Simplified… Published by ACKNOWLEDGEMENTS CONTENTS We gratefully acknowledge the support and funding provided by the Ontario Ministry of Health 1. The Basics of Coagulation and Clot Breakdown . 4–7 and Long-Term Care. 2. Routine Coagulation Tests . 8–17 Special thanks to the following people and organizations who provided their expertise in Evaluating coagulation in the laboratory . 8 reviewing the content of this handbook: Sample collection for coagulation testing . 9 Prothrombin Time (PT) . 10 L Gini Bourner (QMP-LS Hematology Committee) International Normalized Ratio (INR) . 11 L Dr. Jeannie Callum Activated Partial Thromboplastin Time (APTT) . 12 L Dr. Allison Collins Thrombin Time (TT) . 13 Fibrinogen . 14 L Dr. William Geerts D-dimer . 15 L Dr. Alejandro Lazo-Langner Anti-Xa assay . 16 L Dr. Ruth Padmore (QMP-LS Hematology Committee) Summary . 17 L Anne Raby (QMP-LS Hematology Committee) 3. Anticoagulant Drugs . 18–25 L Dr. Margaret Rand Unfractionated Hepari n (UFH) . 18 L Dr. Alan Tinmouth Low Molecular Weight Heparins (LMWHs) . 19 Fondaparinux . 20 Warfarin . 21 Thanks also to: Direct Thrombin Inhibitors (DTI) . 23 L Dale Roddick, photographer, Sunnybrook Health Sciences Centre Direct Xa Inhibitors . 25 L Reena Manohar, graphic artist, Sunnybrook Health Sciences Centre 4. Evaluating Abnormal Coagulation Tests . 26–29 L The ECAT Foundation Prolonged PT / INR with normal APTT . 26 CLOT-ED Images used or modified with permission from Prolonged APTT with normal PT / INR . 27 the ECAT Foundation, The Netherlands. Prolonged APTT and PT / INR . 28 Prolonged Thrombin Time (TT) with normal or prolonged APTT and PT / INR . 29 March 2013 5. Approach to the Evaluation of the Bleeding Patient .
    [Show full text]
  • Identification of Platelet Function Defects by Multi-Parameter
    ARTICLE Received 30 Oct 2013 | Accepted 29 May 2014 | Published 16 Jul 2014 DOI: 10.1038/ncomms5257 OPEN Identification of platelet function defects by multi-parameter assessment of thrombus formation Susanne M. de Witt1, Frauke Swieringa1,*, Rachel Cavill2,*, Moniek M.E. Lamers1, Roger van Kruchten1, Tom Mastenbroek1, Constance Baaten1, Susan Coort3, Nicholas Pugh4, Ansgar Schulz5, Inge Scharrer6, Kerstin Jurk6, Barbara Zieger7, Kenneth J. Clemetson8, Richard W. Farndale9, Johan W.M. Heemskerk1,* & Judith M.E.M. Cosemans1,* Assays measuring platelet aggregation (thrombus formation) at arterial shear rate mostly use collagen as only platelet-adhesive surface. Here we report a multi-surface and multi-para- meter flow assay to characterize thrombus formation in whole blood from healthy subjects and patients with platelet function deficiencies. A systematic comparison is made of 52 adhesive surfaces with components activating the main platelet-adhesive receptors, and of eight output parameters reflecting distinct stages of thrombus formation. Three types of thrombus formation can be identified with a predicted hierarchy of the following receptors: glycoprotein (GP)VI, C-type lectin-like receptor-2 (CLEC-2)4GPIb4a6b1, aIIbb34a2b14CD36, a5b1, avb3. Application with patient blood reveals distinct abnormalities in thrombus formation in patients with severe combined immune deficiency, Glanzmann’s thrombasthenia, Hermansky–Pudlak syndrome, May–Hegglin anomaly or grey platelet syn- drome. We suggest this test may be useful for the diagnosis of patients with suspected bleeding disorders or a pro-thrombotic tendency. 1 Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands. 2 Department of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands.
    [Show full text]
  • GPR56/ADGRG1 Is a Platelet Collagen-Responsive GPCR and Hemostatic Sensor of Shear Force
    GPR56/ADGRG1 is a platelet collagen-responsive GPCR and hemostatic sensor of shear force Jennifer Yeunga, Reheman Adilia, Emily N. Stringhama, Rong Luob, Alexander Vizurragaa, Luciana K. Rosselli-Muraia, Hannah M. Stovekena, Maiya Yua, Xianhua Piaob,c, Michael Holinstata,d, and Gregory G. Talla,1 aDepartment of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI 48109; bDepartment of Medicine, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115; cNewborn Brain Research Institute, Department of Pediatrics, Weill Institute for Neuroscience, University of California, San Francisco, CA 94158; and dDepartment of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 Edited by Robert J. Lefkowitz, Howard Hughes Medical Institute, Durham, NC, and approved September 14, 2020 (received for review May 6, 2020) Circulating platelets roll along exposed collagen at vessel injury The differences in the experimental approaches used to inves- sites and respond with filipodia protrusion, shape change, and tigate platelet responses to collagen have offered varied inter- surface area expansion to facilitate platelet adhesion and plug pretations of whether GPVI is the key signaling receptor that acts formation. Various glycoproteins were considered to be both to initiate platelet activation (2, 7, 8, 13). For example, exogenous collagen responders and mediators of platelet adhesion, yet the collagen promotes sustained GPVI/Fc Receptor gamma (FcRγ) signaling kinetics emanating from these receptors do not fully signaling through phospholipase Cγ2(PLCγ2), but the Ca+2 mo- account for the rapid platelet cytoskeletal changes that occur in bilization output and kinetics of this multistep signaling pathway blood flow.
    [Show full text]